News & Views | Telix Pharmaceuticals Limited

Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide

Telix today announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of The University of Queensland (UQ), to develop a radiolabelled molecule targeting an immune checkpoint protein. The announcement was made at the AusBiotech 2022 national conference, currently being held in Perth, Western Australia.

TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM

Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of studies evaluating CAIX expression in cancers other than clear cell renal cell carcinoma (ccRCC), supporting Telix’s goal to rapidly expand the CAIX program into other indications beyond kidney cancer.

Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate

First Patient Enrolled in ProstACT TARGET Study

Telix and GenesisCare, the largest provider of integrated cancer care in Australia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix’s prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients experiencing a first recurrence of prostate-specific antigen (PSA) after initial therapy for prostate cancer.

Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data

Telix today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ ¹³¹I] iodo-phenylalanine, or ¹³¹I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma multiforme (GBM).

Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment

Telix and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France.

APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging

Telix today reports on regulatory progress for the Company’s core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress in the major market of China with its strategic partner Grand Pharmaceutical Group Limited (Grand Pharma).

BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging

Telix and BAMF Health use Illuccix® for the first time with uEXPLORER® total-body PET scanner for prostate cancer imaging

ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment

Telix Announces a Final Patient Dosed and Recruitment Completed into the Phase III Pivotal ZIRCON Study of TLX250-CDx for Kidney Cancer Imaging

First Patient Dosed in Phase II Renal Cancer Theranostics Study

Telix announces that a first patient has been dosed in the ‘STARLITE 2’ Phase II study of the Company’s investigational renal cancer therapy at MSK in New York.